10:58:10 EST Thu 21 Nov 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
CO2 Gro Inc
Symbol GROW
Shares Issued 67,651,004
Close 2019-09-24 C$ 0.235
Recent Sedar Documents

CO2 talks up tobacco grow trial results for pharma firm

2019-09-24 13:14 ET - News Release

Mr. John Archibald reports

CO2 GRO INC. ANNOUNCES POSITIVE TOBACCO GROW TRIAL RESULTS FOR A BIOPHARMA COMPANY

CO2 Gro Inc. has released statistically significant positive results from a tobacco plant R&D (research and development) grow trial for a biopharmaceutical company. The customer, which has requested not to be named, as per the non-disclosure agreement signed by the parties, currently produces and sells a human drug that is extracted from inoculating young tobacco plant leaves with a specific bacterium. The customer also has a pipeline of other human drugs in development that will be produced using the same plant inoculation process.

The trial was conducted by the University of Guelph. Preinoculated tobacco plants were grown using the company's CO2 (carbon dioxide) delivery solutions versus a control of no CO2. The results in the attached table once again confirm CO2 delivery solutions' ability to significantly enhance the growth of leafy plants.

Measure        Percentage increase/decrease

Height                                48.9%                       
Wet weight                             112%                        
Dry weight                             133%                        
Leaf area                              147%                        

Numerous other biopharmaceutical companies around the world are producing high-value medicines and vaccines extracted from inoculated or genetically modified tobacco, potato or other leaves. As a 2018 article from the TechnologyWorks website describes, tobacco plants can become "organic mini-factories producing vaccines and new drugs."

John Archibald, chief executive officer, commented: "The results once again underscore the effectiveness of CO2 delivery solutions on a variety of plants. Our biopharma customer will now conduct a grow trial on postinoculated tobacco plants using CO2 delivery solutions to assess the impact on increased medicinal content in the plant. Upon a successful postinoculation trial, the discussion with the customer will progress towards a commercial installation at their facility and open the market to other similar customers in the industry."

About CO2 Gro Inc.

The company's mission is to accelerate all indoor and outdoor value plant growth naturally, safely and economically using its patented and advanced CO2 delivery solutions technology.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.